Tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A cost-effectiveness analysis.
<h4>Objective</h4>This study aims to conduct a cost-effectiveness analysis of tislelizumab in combination with platinum and etoposide compared to the standard treatment of etoposide and platinum as first-line therapy for extensive-stage small cell lung cancer(ES-SCLC) from the Chinese me...
Saved in:
| Main Authors: | Zhiwei Zheng, Huide Zhu, Ling Fang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0320189 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Toripalimab plus chemotherapy versus chemotherapy as first-line therapy for extensive-stage small cell lung cancer: a cost-effectiveness analysis
by: Longfeng Zhang, et al.
Published: (2025-07-01) -
Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer.
by: Zhiwei Zheng, et al.
Published: (2025-01-01) -
Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer
by: Zhiwei Zheng, et al.
Published: (2025-01-01) -
First-line chemotherapy with tislelizumab for patients with extensive-stage small cell lung cancer: a cost-effectiveness analysis
by: Rong Long, et al.
Published: (2024-12-01) -
Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for extensive-stage small cell lung cancer from the perspective of the healthcare system in China
by: Feng Chen, et al.
Published: (2025-05-01)